EIDX.OQ
Latest Trade
128.44USDChange
5.91(+4.82%)Volume
30,997Today's Range
-
128.6152 Week Range
-
132.54As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 122.53 |
|---|---|
Open | 120.92 |
Volume | 30,997 |
3M AVG Volume | 3.03 |
Today's High | 128.61 |
Today's Low | 119.74 |
52 Week High | 132.54 |
52 Week Low | 28.39 |
Shares Out (MIL) | 38.87 |
Market Cap (MIL) | 4,763.10 |
Forward P/E | -41.63 |
Dividend (Yield %) | -- |
BridgeBio Pharma And Eidos Therapeutics Approve Co's Acquisition Of Eidos Therapeutics
Eidos Therapeutics Posts Q3 Loss Per Share $0.79
Eidos Therapeutics Reports Second Quarter Results
Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on addressing the unmet need in diseases caused by transthyretin (TTR), amyloidosis (ATTR). It focuses on treating the disease by targeting them at their collective source by stabilizing TTR. The Company’s product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 binds and stabilizes TTR in the blood, preventing the formation of amyloid and halting progression of the disease.
Industry
Biotechnology & Drugs
Contact Info
101 Montgomery St Ste 2550
SAN FRANCISCO, CA
94104-4158
United States
+1.650.3919740
http://eidostx.comExecutive Leadership
Jonathan C. Fox
President, Chief Medical Officer
Neil Kumar
Chief Executive Officer, Director
Uma Sinha
Chief Scientific Officer, Director
Cameron Turtle
Chief Business Officer
Suzanne Sawochka Hooper
Independent Director
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 37,504.69 |
Price To Book (MRQ) | 38.49 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 13.62 |
LT Debt To Equity (MRQ) | 13.62 |
Return on Investment (TTM) | -63.75 |
Return on Equity (TTM) | -59.27 |
* EIDOS THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND BUSINESS UPDATE
* EIDOS THERAPEUTICS - IN LIGHT OF COVID-19, EXPERIENCING DELAYS IN OR TEMPORARY SUSPENSION OF ENROLLMENT OF PATIENTS IN ONGOING CLINICAL TRIALS
* EIDOS THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2019 FINANCIAL RESULTS AND BUSINESS UPDATE
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.